POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo pill shows promise for rare bone marrow cancer
Disease control OngoingThis study tests whether adding a new drug (pelabresib) to the standard treatment (ruxolitinib) works better than the standard treatment alone for people with myelofibrosis, a rare bone marrow disorder. About 430 adults who have not received prior JAK inhibitor therapy will take …
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 08:31 UTC
-
New drug hope for rare bone marrow cancer
Disease control OngoingThis study tests a drug called canakinumab in people with myelofibrosis, a rare bone marrow disorder. The goal is to see if it can improve symptoms, reduce spleen size, or help with anemia. About 14 adults will receive injections every 3 weeks for 6 months. The study is currently…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated May 26, 2026 08:24 UTC
-
New hope for anemia in myelofibrosis patients
Disease control OngoingThis study tests a new drug (INCB000928) given alone or with ruxolitinib for people with myelofibrosis who have anemia or need regular blood transfusions. The goal is to find a safe dose that improves red blood cell counts and reduces transfusion needs. About 84 adults will take …
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
New hope for rare bone marrow cancer patients with dangerous low platelets
Disease control OngoingThis study tests a drug called pacritinib against standard treatments in about 400 people with myelofibrosis, a type of bone marrow cancer, who also have very low platelet counts (below 50,000). The goal is to see if pacritinib can shrink the spleen and improve symptoms like bell…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated May 18, 2026 12:13 UTC